Form 4: Denali Therapeutics Chief Medical Officer Reports Stock and Option Transactions

Denali Therapeutics' Chief Medical Officer, Carole Ho, reported the acquisition of stock and stock options, along with adjustments to existing holdings, on January 3, 2025.

Summary

• Carole Ho, Chief Medical Officer of Denali Therapeutics, reported several transactions involving the company's stock on January 3, 2025.
• These transactions include the acquisition of 54,180 shares of common stock through Restricted Stock Units (RSUs) and the grant of an option to purchase 162,540 shares.
• The RSUs vest over four years, with 25% vesting on January 3, 2026, and the remainder vesting annually thereafter.
• The stock options also vest over time, with 25% vesting on January 3, 2026, and the remainder vesting monthly over the following three years.
• Ms. Ho also has indirect ownership of 183,219 shares through a family trust and 25,000 shares through another trust for her children.
• Following these transactions, Ms. Ho directly owns 190,835 shares and 162,540 stock options, and indirectly owns 208,219 shares.

Sentiment

Score: 7

Explanation: The document reflects standard insider transactions, which are generally viewed neutrally to slightly positive as they indicate executive alignment with company performance.

Positives

• The acquisition of stock and stock options by the Chief Medical Officer indicates confidence in the company's future performance.
• The vesting schedules for the RSUs and stock options align with long-term value creation for the company.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a long-term commitment by the Chief Medical Officer to the company's success.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the holdings of key executives.

Comparison to Industry Standards

• The vesting schedules for the RSUs and stock options are typical for executive compensation packages in the biotechnology industry.
• Similar companies like Biogen and Vertex Pharmaceuticals also use stock options and RSUs as part of their executive compensation plans.
• The reporting of these transactions is in line with SEC regulations for insider trading.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as they indicate the Chief Medical Officer's commitment to the company.
• The vesting schedules for the RSUs and stock options align with long-term value creation for the company, which is beneficial for shareholders.

Key Dates

Keywords

Denali Therapeutics, DNLI, Carole Ho, Chief Medical Officer, Stock Options, Restricted Stock Units, RSUs, Insider Trading, Beneficial Ownership, SEC Form 4